[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 37809
1. Al-Wadei HA, Schuller HM: Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol; 2009 Aug;218(4):437-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas.
  • Small airway-derived pulmonary adenocarcinoma (PAC) and pancreatic ductal adenocarcinoma (PDAC) are among the most common human cancers and smoking is a risk factor for both.
  • Emerging research has identified cAMP signalling stimulated by the stress neurotransmitters adrenaline and noradrenaline as an important stimulator of adenocarcinomas, including PAC and PDAC.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):294-9 [15900604.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):639-48 [16091975.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):431-5 [16391865.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):618-28 [16269536.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1370-80 [16206275.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Cancer Biol Ther. 2006 May;5(5):511-7 [16582591.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):403-11 [17067750.001]
  • [Cites] Toxicol Sci. 2007 Mar;96(1):21-9 [17003101.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):261-7 [17498763.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6863-71 [17638897.001]
  • [Cites] Cancer Genomics Proteomics. 2007 Jan-Feb;4(1):35-42 [17726239.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1737-44 [17557921.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2002 Mar;29(3):181-8 [11906480.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] J Neurobiol. 2002 Dec;53(4):606-17 [12436424.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6467-9 [12438237.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;978:405-12 [12582069.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):91-111 [12920702.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):11-8 [15196729.001]
  • [Cites] Neurosci Lett. 2004 Nov 3;370(1):80-3 [15489022.001]
  • [Cites] Biochem Pharmacol. 1989 Oct 15;38(20):3439-42 [2573356.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1960-5 [2306745.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8 [2159143.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):105-16 [2233792.001]
  • [Cites] Neuron. 1991 Jul;7(1):91-100 [2069816.001]
  • [Cites] IARC Sci Publ. 1991;(105):54-61 [1855913.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):767-78 [18098271.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3746-53 [18559592.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):655-71 [18594207.001]
  • [Cites] Br J Pharmacol. 2008 Aug;154(8):1558-71 [18500366.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):345-56 [18693168.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68 [18640919.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1979-85 [18310090.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1367-78 [11579145.001]
  • [Cites] Neurosci Lett. 2001 Oct 26;312(3):161-4 [11602335.001]
  • [Cites] Carcinogenesis. 1993 Mar;14(3):451-5 [8453721.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2498-501 [8495411.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3504-8 [7627955.001]
  • [Cites] Crit Rev Toxicol. 1996;26(2):163-81 [8688159.001]
  • [Cites] Prog Brain Res. 1996;109:125-37 [9009699.001]
  • [Cites] Cardiovasc Drugs Ther. 1997 Jan;10(6):657-65 [9110108.001]
  • [Cites] Prog Neurobiol. 1997 Oct;53(2):199-237 [9364611.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1377-84 [10076528.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Dig Dis Sci. 1999 Jul;44(7):1303-11 [10489910.001]
  • (PMID = 19274673.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042829; United States / NCI NIH HHS / CA / R01 CA096128; United States / NCI NIH HHS / CA / R01CA042829; United States / NCI NIH HHS / CA / R01CA096128
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Nitrosamines; 0 / Receptors, Nicotinic; 56-12-2 / gamma-Aminobutyric Acid; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; E0399OZS9N / Cyclic AMP; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  • [Other-IDs] NLM/ NIHMS380611; NLM/ PMC3372983
  •  go-up   go-down


2. Wang Y, Zhang X, Wang B, Wang Z, Chu D, Sun Y: [Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma.]. Zhongguo Fei Ai Za Zhi; 2008 Feb 20;11(1):137-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma.].
  • BACKGROUND: To evaluate the efficacy and safety of gefitinib, an orally active epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), in elderly patients with other types of adenocarcinoma.
  • All these patients received gefitinib 250mg/d in Cancer Institute ( Hospital ), Chinese Aacademy of Medical Sciences until disease progression or toxicities not tolerated by patient.
  • RESULTS: Overall response rate and disease controlled rate (DCR) of gefitinib were 24.6% and 88.4% respectively.
  • Furthermore, the overall survival times were significantly longer in patients of Bronchioloalveolar carcinoma, female and nonsmokers than patients with adenocarcinoma, and male and smokers.
  • CONCLUSIONS: Gefitinib is effective and safe in elderly patients with advanced adenocarcinomas of the lung.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727283.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol; 2006 Jun 20;24(18):2897-902
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
  • PURPOSE: Different prognostic factors stratify patients with pancreatic adenocarcinoma.
  • The purpose of this study was to determine whether preoperative CA19-9 levels can predict stage of disease or survival and whether a change in preoperative to postoperative CA19-9 or the postoperative CA19-9 predicts overall survival.
  • PATIENTS AND METHODS: Four hundred twenty-four consecutive patients with pancreatic adenocarcinoma underwent resection between January 1, 1985 and January 1, 2004.
  • RESULTS: Of the 176 patients, 128 (73%) had T3 lesions, and 99 (56%) had N1 disease; 138 patients (78%) underwent pancreaticoduodenectomy.
  • CONCLUSION: In patients with pancreatic adenocarcinoma, preoperative CA19-9 correlates with stage of disease.
  • [MeSH-major] Adenocarcinoma. CA-19-9 Antigen / blood. Pancreatectomy. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2003 Sep;138(9):951-5; discussion 955-6 [12963650.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):835-40 [12820309.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5489-92 [6193872.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):644-9 [15197014.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Science. 1981 Apr 3;212(4490):53-5 [6163212.001]
  • [Cites] Br J Cancer. 1998;77(2):325-8 [9461005.001]
  • [Cites] Ann Surg Oncol. 1997 Oct-Nov;4(7):551-6 [9367020.001]
  • [Cites] Clin Chem. 1983 Mar;29(3):549-52 [6825270.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1286-92 [16332484.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2433-5 [10470171.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:118-21 [10436801.001]
  • [Cites] Semin Surg Oncol. 1998 Jul-Aug;15(1):15-22 [9671952.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):253-9 [9496523.001]
  • [CommentIn] J Clin Oncol. 2006 Dec 10;24(35):5610; author reply 5611 [17158548.001]
  • (PMID = 16782929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  • [Other-IDs] NLM/ NIHMS519545; NLM/ PMC3817569
  •  go-up   go-down


Advertisement
4. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg; 2007 Jul;246(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
  • OBJECTIVE: To determine whether the length of esophageal resection or the operative approach influences outcome for patients with adenocarcinoma of the gastroesophageal junction (GEJ).
  • METHODS: Patients with Siewert I, II, or III adenocarcinoma who underwent complete gross resection without neoadjuvant therapy were identified from a prospectively maintained database.
  • CONCLUSIONS: In patients not receiving neoadjuvant therapy, the goal for patients with adenocarcinoma of the GEJ should be R0 resection including at least 15 lymph nodes, preferably with 5 cm of grossly normal in situ proximal esophagus for those with <or=6 positive lymph nodes.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Feb 15;103(4):702-7 [15641033.001]
  • [Cites] J Am Coll Surg. 2004 Dec;199(6):880-6 [15555971.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Dis Esophagus. 2001;14(1):32-6 [11422303.001]
  • [Cites] Dis Esophagus. 2001;14(2):104-9 [11553218.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):520-30; discussion 530-1 [11573045.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1223-9 [11953876.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):419-22 [11995464.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1156-63 [12190682.001]
  • [Cites] Dig Surg. 2002;19(4):269-74; discussion 275 [12207069.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1192-7 [14630753.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):419-24 [15056079.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] Br J Surg. 1979 Sep;66(9):609-12 [497643.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):173-6 [3947154.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):188-95 [3947155.001]
  • [Cites] Ann Surg. 1987 Feb;205(2):189-94 [3813689.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):282-6 [1607041.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Feb;42(1):37-42 [7782032.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 May;113(5):836-46; discussion 846-8 [9159617.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):678-83; discussion 683-5 [9230808.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Am J Surg. 1998 Sep;176(3):286-90 [9776161.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):352-7 [9783780.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Eur J Surg. 1998 Oct;164(10):759-64 [9840305.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jun;15(6):769-73 [10431857.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):594-601 [10589596.001]
  • (PMID = 17592282.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899203
  •  go-up   go-down


5. Zhang S, Wang M, Xue YH, Chen YP: Cerebral metastasis from hepatoid adenocarcinoma of the stomach. World J Gastroenterol; 2007 Nov 21;13(43):5787-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral metastasis from hepatoid adenocarcinoma of the stomach.
  • We first report a rare case of metastasis from gastric hepatoid adenocarcinoma (HAC) to cerebral parenchyma, in a 50-year-old Chinese patient.
  • He complained of a one-month history of a paroxysm of headache in the left temple and pars parietalis accompanied with binocular caligation caligo, insensible feeling of limbs and transient anepia.
  • Three years ago, the patient accepted total gastrectomy as he was pathologically diagnosed at gastroscopy having an adenocarcinoma.
  • Before operation of the brain metastasis, no obvious abnormality was found in liver by ultrasound.
  • The differential diagnosis of brain metastasis from metastatic tumors should use a panel of antibodies to avoid confusing with the brain metastasis of hepatocellular carcinoma (HCC).
  • This paper describes this rare case of metastasis from gastric hepatoid adenocarcinoma to cerebral parenchyma, and provides a review of the literature concerning its histopathological and immunohistochemical characteristics.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963312.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4171272
  •  go-up   go-down


6. Noorani S, Rao AR, Callaghan PS: Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma. Int Urol Nephrol; 2007;39(3):837-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma.
  • Excision biopsy revealed adenocarcinoma.
  • Immunohistochemical staining demonstrated that the tumour cells were strongly suggestive of a metastatic lesion from the colon.
  • Subsequent investigations revealed that the patient did indeed have a sigmoid adenocarcinoma and underwent chemotherapy with a view to anterior resection and pelvic exenteration.
  • Treatment options have to be individualised to the extent of the disease and the symptoms of the patient.
  • A biopsy of the lesion is the only way of confirming diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Sigmoid Neoplasms / pathology. Urethral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318345.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


7. Ruddat VC, Whitman S, Klein RD, Fischer SM, Holman TR: Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. Prostate; 2005 Jul 1;64(2):128-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma.
  • METHODS: The abundance of several important proteins in prostate tissue was compared between wild-type mouse dorsal prostate and well-differentiated transgenic adenocarcinoma mouse prostate (TRAMP) mouse dorsal prostates, and between wild-type mouse dorsal prostate and poorly-differentiated TRAMP mouse tumor tissue.
  • RESULTS: In TRAMP dorsal prostates with well-differentiated adenocarcinoma, there were few significant changes in the protein abundances compared to wild-type dorsal prostates, with the exception of increases in proliferating cell nuclear antigen (PCNA) and beta tubulin, two proteins implicated in cell proliferation, and a more than 2-fold increase in Hsp60, a protein involved in the suppression of apoptosis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Calcium Signaling / physiology. Prostatic Neoplasms / physiopathology. Proteins / physiology
  • [MeSH-minor] Animals. Disease Models, Animal. Disease Progression. Down-Regulation. Male. Mice. Neoplasm Staging. Proteomics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15666362.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM56062-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


8. Morandi L, Asioli S, Cavazza A, Pession A, Damiani S: Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung. Lung Cancer; 2007 Apr;56(1):35-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung.
  • Atypical adenomatous hyperplasia (AAH) has been recently defined by WHO as a small lesion, not exceeding 5mm in major axis, composed of slightly enlarged alveolar septa lined by pneumocytes with plump, atypical nuclei.
  • AAH is frequently found in tissue surrounding lung adenocarcinoma and is considered a precursor of this subtype of lung cancer by many Authors.
  • However, the genetic relationship between adenocarcinoma and the associated foci of AAH is not well defined.
  • In particular, it is not clear whether multiple foci of AAH and of adenocarcinoma in the same patients are clonally related to each other or represent independent neoplastic foci.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenomatosis, Pulmonary / genetics. Lung Neoplasms / genetics. Precancerous Conditions / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241687.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


9. Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys; 2007 May 1;68(1):178-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
  • PURPOSE: To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival.
  • METHODS AND MATERIALS: A total of 34 cases of adenocarcinoma of the DCBD were treated with PD and adjuvant chemoradiation at Johns Hopkins Hospital between 1994 and 2003.
  • Death occurred in 21 of 34 patients (62%) during the follow-up period, all from progressive, distant metastatic disease.
  • CONCLUSIONS: Adjuvant chemoradiation after PD for adenocarcinoma of the DCBD may improve local control and overall survival.
  • The predominant mode of failure is distant metastatic disease, highlighting the need for improved systemic therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276614.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Kaneda H, Sakaida N, Saito T, Maniwa T, Uemura Y, Saito Y: Appearance of bronchioloalveolar carcinoma and the rapid progression into invasive papillary adenocarcinoma. Gen Thorac Cardiovasc Surg; 2009 Apr;57(4):224-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appearance of bronchioloalveolar carcinoma and the rapid progression into invasive papillary adenocarcinoma.
  • The prognostic importance of bronchioloalveolar carcinoma in comparison to the invasive subtypes needs to be studied, although the natural history of a pure bronchioloalveolar carcinoma is still unclear.
  • We report the appearance of a pure ground-glass opacity that demonstrates rapid progression into a solid component in the central area, pathologically revealing a minimally invasive papillary adenocarcinoma.
  • Considering the findings of previous reports, as well as our case, we need to pay careful attention to the follow-up of a patient who has even a pure ground-glass opacity when the patient had a history of an invasive lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Papillary / pathology. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Aged. Disease Progression. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367459.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Hart B, Erickson R, LeBlanc C, Hix-Hernandez S, Shabahang M: Adenocarcinoma of the distal pancreas presenting as an intrathoracic mass. Curr Surg; 2006 Sep-Oct;63(5):330-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the distal pancreas presenting as an intrathoracic mass.
  • Pancreatic masses within the body or tail usually have delayed diagnosis secondary to the lack of any early findings, which, in turn, leads to a higher incidence of involvement of adjacent structures, such as the superior mesenteric artery, portal vein, or superior mesenteric vein.
  • The authors report a case of advanced pancreatic adenocarcinoma in which the anomalous thoracic location of the organ resulted in the tumor being resectable.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971204.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wang Y, Xie SL, Wang CF, Liu SM, Shan Y, Zhao DB, Liu Q, Luo W, Zhao P: [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1089-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions].
  • OBJECTIVE: To improve the diagnosis and treatment of non-ductal pancreatic adenocarcinoma-occupying lesions.
  • METHODS: A retrospective analysis was made for 114 cases of pancreatic non-ductal adenocarcinoma-occupying pathologically confirmed lesions. RESULTS:.
  • (5) pathologic analysis revealed 35 solid pseudopapillary neoplasm of pancreas, 28 pancreatic endocrine tumors, 18 focal chronic pancreatitis, 11 serous cystic neoplasms, 9 mucinous cystic neoplasms, 4 pancreatic cysts, 3 acinar cell carcinomas, 2 pancreatic cavernous hemangiomas, 1 sarcoma of pancreas, 1 sarcomatoid carcinoma of pancreas, 1 pancreatic schwannoma and 1 pancreatic neuroblastoma.
  • CONCLUSION: The non-ductal pancreatic adenocarcinoma-occupying lesions have no specific clinical presentation or serum tumor marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646423.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


13. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia / pathology. Cardia / surgery. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sakuma Y, Takeuchi T, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Ohgane N, Yokose T, Kameda Y, Tsuchiya E, Miyagi Y: Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. J Pathol; 2010 Apr;220(5):574-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src.
  • Although several lung adenocarcinoma cell lines were shown to repress anoikis through the activation of Src, it remains unknown whether Src actually plays a crucial role in anoikis resistance in lung adenocarcinoma tissues.
  • We examined 20 human lung adenocarcinoma tissues with lymphatic permeation and nine cell lines to investigate whether intralymphatic floating carcinoma cells in the tissues, used as an in vivo model of anoikis resistance, actually suppressed anoikis and whether cell lines in suspension culture, an in vitro model of anoikis resistance, survived through Src activation.
  • These results indicate that Src, but not Abl or Kit, plays an essential role in the development of anoikis resistance in lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Anoikis / physiology. Lung Neoplasms / pathology. Lymphatic Vessels / pathology. Neoplastic Cells, Circulating / pathology. src-Family Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aniline Compounds / pharmacology. Antineoplastic Agents / pharmacology. Benzamides. Cadherins / metabolism. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Proteins / metabolism. Nitriles / pharmacology. Oncogene Proteins v-abl / antagonists & inhibitors. Phosphorylation. Piperazines / pharmacology. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Pyrazoles / pharmacology. Pyrimidines / pharmacology. Quinolines / pharmacology. Spheroids, Cellular. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146241.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Nitriles; 0 / Oncogene Proteins v-abl; 0 / Piperazines; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Quinolines; 5018V4AEZ0 / bosutinib; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


15. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767067.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Béllannée G, Brunet R, Collet D, Masson B: Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg; 2005 Sep;201(3):359-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
  • STUDY DESIGN: Since 1998, 61 patients with radiographically unresectable, pathologically confirmed pancreatic adenocarcinoma have received standard fractionation radiation therapy (total dose, 45 Gy at 1.8 Gy, 5 d/wk) with chemotherapy, which included a continuous infusion of fluorouracil (5-FU: 650 mg/m(2)/D1-D5 and D21-D25) and cisplatin (80 mg/m(2)/bolus D2 and D22).
  • RESULTS: Thirty-eight of 61 (62%) restaged patients demonstrated a disease progression.
  • CONCLUSIONS: Locally advanced, unresectable pancreatic adenocarcinoma may be downstaged by chemoradiotherapy to allow for surgical resection.
  • Patients whose cancer becomes resectable have a median survival at least comparable with survival after resection for initially resectable pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / therapy. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Neoplasm Staging. Palliative Care. Pancreas / pathology. Radiotherapy Dosage. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Abate E, DeMeester SR, Zehetner J, Oezcelik A, Ayazi S, Costales J, Banki F, Lipham JC, Hagen JA, DeMeester TR: Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg; 2010 Apr;210(4):428-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing.
  • BACKGROUND: To determine the optimal follow-up strategy after esophagectomy for adenocarcinoma of the esophagus or gastroesophageal junction by evaluating the timing of recurrence and the method that first detected the recurrence.
  • STUDY DESIGN: Between 1991 and 2007, 590 patients had an esophagectomy for adenocarcinoma.
  • CONCLUSIONS: Frequent early follow-up is appropriate after esophagectomy for adenocarcinoma because >90% of recurrences will occur by 3 years after esophagectomy alone and by 2 years following neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. California. Chemotherapy, Adjuvant. Esophagogastric Junction. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20347734.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Friedlander MA, Rudomina D, Lin O: Effectiveness of the Thin Prep Imaging System in the detection of adenocarcinoma of the gynecologic system. Cancer; 2008 Feb 25;114(1):7-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of the Thin Prep Imaging System in the detection of adenocarcinoma of the gynecologic system.
  • METHODS: TIS evaluated TP tests with histologic confirmation of adenocarcinoma involving the gynecologic system were included in the current study.
  • The majority of these false-negative cases (6 of 9 cases) derived from endometrial adenocarcinoma.
  • No cytologic evidence of a glandular abnormality was found in the 54 remaining cases.
  • CONCLUSIONS: The TIS was found to be effective in identifying atypical glandular cells in specimens containing malignant glandular cells, leading to a full review of the slide.
  • [MeSH-major] Adenocarcinoma / pathology. Diagnostic Imaging / methods. Genital Neoplasms, Female / pathology. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18085633.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Baumann S, Keller G, Pühringer F, Napieralski R, Feith M, Langer R, Höfler H, Stein HJ, Sarbia M: The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer; 2006 Jul 15;119(2):264-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma.
  • In colorectal cancer and lung cancer, hypermethylation of MGMT has been correlated with p53 mutation.
  • In the present study, 132 samples of esophageal adenocarcinoma and 58 samples of normal esophageal tissue were investigated for MGMT hypermethylation status by methylation-specific real-time PCR and results were correlated to clinicopathological parameters, patient's survival, p53 mutation and expression of p53 protein and MGMT protein.
  • In conclusion, MGMT hypermethylation in esophageal adenocarcinoma is a frequent event that is associated with loss of MGMT protein expression but not with patient's outcome.
  • [MeSH-major] Adenocarcinoma / metabolism. DNA Methylation. DNA, Neoplasm / metabolism. Esophageal Neoplasms / metabolism. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477636.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


20. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT: Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol; 2010;5:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.
  • PURPOSE: To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma.
  • However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • (PMID = 21059255.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987939
  •  go-up   go-down


21. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK: Somatic mutations affect key pathways in lung adenocarcinoma. Nature; 2008 Oct 23;455(7216):1069-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations affect key pathways in lung adenocarcinoma.
  • Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas.
  • These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B.
  • Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.


22. Kondou M, Nagayasu T, Hidaka S, Tsuchiya T, Takeshita H, Yasutake T, Yano H, Minami H, Iwasaki K: Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients. Tohoku J Exp Med; 2009 Feb;217(2):101-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients.
  • Lung cancer commonly occurs in individuals who are 60 years of age or older.
  • Lung cancer in patients younger than 40 years of age is rare and is often advanced when discovered.
  • However, the biological features of lung cancer in young adults have not yet been fully elucidated.
  • This study was conducted to determine the role of p53 expression and neoangiogenesis in lung adenocarcinomas of young patients.
  • Lung adenocarcinomas, which were surgically resected from 20 patients younger than 40 years of age between 1977 and 1996, were compared with lung adenocarcinomas selected with random sampling from 45 patients older than 60 years of age.
  • Lung adenocarcinomas with p53-positive staining showed higher expression of VEGF protein than p53-negative tumors in both the young and the elderly groups.
  • Lung adenocarcinoma occurring in young patients tends to have a poorer prognosis, and angiogenesis of lung adenocarcinoma in young patients is more closely correlated with p53 expression than in elderly patients.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Lung Neoplasms / blood supply. Lung Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212102.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


23. Spiess PE, Correa JJ: Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol; 2009 Sep-Oct;35(5):609
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma.
  • INTRODUCTION AND OBJECTIVE: Standard treatment for urachal adenocarcinomas is open partial cystectomy and urachal resection; however, minimally invasive surgical approaches including laparoscopic and recently described robotic assisted laparoscopic partial cystectomy and urachal resection is feasible with potential less morbidity.
  • A case of robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma is presented.
  • Transurethral biopsy confirmed a urachal adenocarcinoma.
  • RESULTS: Final pathology reported a pT2N0Mx adenocarcinoma with negative margins and negative pelvic lymph nodes.
  • CONCLUSIONS: Robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma of the bladder is feasible even in challenging cases.
  • [MeSH-major] Adenocarcinoma / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860941.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Video-Audio Media
  • [Publication-country] Brazil
  •  go-up   go-down


24. Chandana S, Mahadevan D: Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype? Expert Rev Mol Med; 2009;11:e34
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
  • Biological complexity, inaccessible anatomical location, nonspecific symptoms, lack of a screening biomarker, advanced disease at presentation and drug resistance epitomise pancreatic ductal adenocarcinoma (PDA) as a poor-prognosis, lethal disease.
  • Twenty-five years of research (basic, translational and clinical) have barely made strides to improve survival, mainly because of a fundamental lack of knowledge of the biological processes initiating and propagating PDA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919723.001).
  • [ISSN] 1462-3994
  • [Journal-full-title] Expert reviews in molecular medicine
  • [ISO-abbreviation] Expert Rev Mol Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Hasegawa S, Yoshikawa T: Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer; 2010 Jun;13(2):63-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.
  • The incidence of adenocarcinoma of the esophagogastric junction (AEG) is dramatically increasing in Western countries, while it is not increasing in Eastern countries.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602191.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


26. Gerber A, Moiton MP, Renou F, Bigourdan JM, Yvin JL: [Intermittent fever: rare expression of an adenocarcinoma of the ampulla of Vater]. Rev Med Interne; 2007 Apr;28(4):263-5
MedlinePlus Health Information. consumer health - Fever.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intermittent fever: rare expression of an adenocarcinoma of the ampulla of Vater].
  • [Transliterated title] Fièvre intermittente: expression rare d'un adénocarcinome de l'ampoule de Vater.
  • PURPOSE: Prolonged intermittent fevers are frequently seen in internal medicine and they constitute a real diagnosis challenge.
  • Infection, auto-immune disease and neoplasy are the most common causes.
  • At first, all his assessments were negative and it's only secondary, as clinical and biological disturbances occur that the diagnosis of adenocarcinoma of the ampulla has been done.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196308.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H: Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg; 2006 Feb;81(2):413-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact.
  • BACKGROUND: A new radiologic classification for small adenocarcinoma is necessary for discussions of limited surgical resection for peripheral lung cancer.
  • METHODS: Between 1999 and 2003, 1,697 consecutive patients underwent pulmonary resection for lung cancer.
  • Three hundred forty-nine of these patients with clinical stage IA lung cancer who had lung peripheral adenocarcinoma, 2 cm or less in size, were investigated retrospectively.
  • CONCLUSIONS: Types 1, 2, 3, and 4 are considered to be radiologic early adenocarcinoma of the lung, and their pathologic features were minimally invasive.
  • On the other hand, type 5 and 6 tumors could have lymph node metastases and are considered to be invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Neoplasm Staging. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Feb;81(2):419-20 [16427824.001]
  • (PMID = 16427823.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W: Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci; 2010 Dec;55(12):3304-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.
  • Esophageal adenocarcinoma is an aggressive malignancy with a poor outcome, and its incidence continues to rise at an alarming rate.
  • Multiple molecular pathways including the epidermal growth factor receptor, vascular endothelial growth factor, v-erb-b2 erythroblastic leukemia viral oncogene homolog (ERBB2), and Aurora kinase pathways are activated in many esophageal adenocarcinomas.
  • Research on the mechanisms by which these pathways contribute to disease progression has resulted in numerous biologic agents and small molecules with the potential to improve outcome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Molecular Targeted Therapy
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Aurora Kinases. Barrett Esophagus / pathology. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Esophagectomy. Humans. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / physiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2004 Aug 1;87(2):95-104 [15282704.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1282-8 [15167938.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):747-53 [15386389.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1790-800 [15511476.001]
  • [Cites] Surg Gynecol Obstet. 1981 Nov;153(5):690-2 [6794167.001]
  • [Cites] World J Surg. 1987 Aug;11(4):426-32 [3630187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):325-7 [2646253.001]
  • [Cites] Br J Surg. 1990 Aug;77(8):845-57 [2203505.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):213-9 [8098013.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):320-4 [9324146.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Sep;12(3):361-4; discussion 364-5 [9332912.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):579-83 [9635705.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):170-7 [18703277.001]
  • [Cites] J Hepatol. 2009 Mar;50(3):518-27 [19155085.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):866-75 [19060929.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):587-95; discussion 596 [19258071.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):135-52, ix [19327572.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):379-98 [19335272.001]
  • [Cites] J Am Coll Surg. 2009 Apr;208(4):553-6 [19476789.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1547-56 [19509244.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1522-8 [19465425.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5983-91 [20014464.001]
  • [Cites] Breast Cancer Res Treat. 2010 Feb;120(1):47-57 [19301121.001]
  • [Cites] Clin Colorectal Cancer. 2010 Jan;9(1):8-14 [20100683.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6869-75 [17145803.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):120-9 [17143264.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9 [17097832.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):357-63 [17270025.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2006-16 [17001310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4 [18711136.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5437-46 [18765535.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1786(1):60-72 [18662747.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):629-37 [18834407.001]
  • [Cites] Am J Clin Oncol. 2008 Aug;31(4):329-34 [18845990.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8998-9004 [18974145.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2330-4 [18780893.001]
  • [Cites] Gut. 2009 Jan;58(1):5-15 [18664505.001]
  • [Cites] Cancer Lett. 2009 Mar 8;275(1):117-26 [19027227.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):212-22 [18854960.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1010-8 [10512940.001]
  • [Cites] Cancer Invest. 2004;22(5):670-7 [15581047.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):203-11 [15629613.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5005-15 [16049526.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6583-92 [16061638.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5 [16192817.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Surgery. 2005 Nov;138(5):924-31 [16291394.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):95-102 [16317296.001]
  • [Cites] Cancer Causes Control. 2006 Feb;17(1):81-3 [16411056.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):214-20 [16418887.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1814-22 [16217753.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):236-44 [16545878.001]
  • [Cites] Arch Surg. 2006 May;141(5):476-81; discussion 481-2 [16702519.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):449-55 [16849520.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD001556 [16855972.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Diagn Mol Pathol. 2006 Sep;15(3):125-30 [16932066.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):341-8 [17460778.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3100-4 [17505013.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5869-75 [17908981.001]
  • [Cites] J Am Coll Surg. 2007 Dec;205(6):735-40 [18035255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):391-5 [17980508.001]
  • [Cites] Ann Thorac Surg. 2008 Feb;85(2):424-9 [18222237.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):571-6 [18240225.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1688-98 [18311783.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 [18451130.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3081-6; discussion 3086 [18451131.001]
  • [Cites] Anesthesiol Clin. 2008 Jun;26(2):293-304, vi [18456214.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12):1460-5 [17852856.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jun;135(6):1228-36 [18544359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5 [18559552.001]
  • [Cites] Oncology. 2007;73(5-6):281-9 [18477853.001]
  • [Cites] Hepatogastroenterology. 2008 Mar-Apr;55(82-83):475-81 [18613391.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4564-71 [18579663.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Feb;119(2):277-88 [10649203.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Recent Results Cancer Res. 2000;155:29-41 [10693236.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Jul;15(7):730-6 [10937677.001]
  • [Cites] Chest Surg Clin N Am. 2000 Aug;10(3):451-69 [10967750.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] J Cell Biol. 2002 Feb 4;156(3):437-51 [11827981.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4061-4 [12124342.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):303-8 [12611579.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6461-8 [14695149.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):448-53 [15120370.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • (PMID = 20300841.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024975; United States / NCI NIH HHS / CA / T32 CA106183-04; United States / NCI NIH HHS / CA / T32 CA106183; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; United States / NCI NIH HHS / CA / R01 CA133738-01A2; United States / NCI NIH HHS / CA / R01 CA106176-07A1; United States / NCI NIH HHS / CA / CA133738; United States / NCI NIH HHS / CA / CA131225; United States / NCI NIH HHS / CA / R01 CA131225-01A2; United States / NCI NIH HHS / CA / R01 CA133738; United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01 CA131225; United States / NCI NIH HHS / CA / T32 CA106183-05; United States / NCRR NIH HHS / RR / UL1 RR024975; United States / NCRR NIH HHS / RR / UL1 RR024975-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS183809; NLM/ PMC2890301
  •  go-up   go-down


29. Boonsarngsuk V, Suwatanapongched T, Rochanawutanon M, Ngodngamthaweesuk M, Prakardvudhisarn P: Primary polymorphous low-grade adenocarcinoma of the bronchus: complete tumor removal with bronchoscopic resection. Lung Cancer; 2009 Feb;63(2):301-4
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary polymorphous low-grade adenocarcinoma of the bronchus: complete tumor removal with bronchoscopic resection.
  • Primary polymorphous low-grade adenocarcinoma (PLGA) is an uncommon malignant tumor arising from the minor salivary glands, but its occurrence as a primary tumor of the tracheobronchial tree is very rare.
  • [MeSH-major] Adenocarcinoma / surgery. Bronchial Neoplasms / surgery. Bronchoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617289.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


30. Sweets T, Bracken RB, Geisler EJ, Warnick R: Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative. Urology; 2009 Mar;73(3):681.e7-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative.
  • We present a young patient with a prostate-specific antigen value of 26 ng/dL and pathologic Gleason score 4 + 5 = 9 prostatic adenocarcinoma who developed a solitary cerebral metastasis 4 years after radical prostatectomy.
  • With aggressive treatment involving resection of the solitary metastasis and use of local brachytherapy, the patient remains with an undetectable PSA level and without evidence of disease 5 years later.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502485.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Triolo O, Antico F, Mancuso A, Salimbeni V, Nicotina PA: Postmenopausal bleeding and vaginal nodules as the first presenting sign of adenocarcinoma of the gallbladder. Eur J Gynaecol Oncol; 2005;26(5):543-4
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmenopausal bleeding and vaginal nodules as the first presenting sign of adenocarcinoma of the gallbladder.
  • Vaginal submucosal nodules were observed in a 67-year-old woman, with ultrasonographic features of an advanced uterine neoplasm.
  • A mass in the gallbladder fossa was then detected by computed tomography and a primary gallbladder adenocarcinoma was confirmed on ultrasound-guided biopsy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gallbladder Neoplasms / diagnosis. Uterine Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Metastasis. Postmenopause. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285575.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Oohashi E, Kangawa A, Kobayashi Y: Mammary adenocarcinoma in a chipmunk (Tamias sibiricus). J Vet Med Sci; 2009 May;71(5):677-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary adenocarcinoma in a chipmunk (Tamias sibiricus).
  • The mammary mass was surgically excised and was histopathologically diagnosed as mammary adenocarcinoma.
  • This is the first report of a mammary tumor in chipmunks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19498300.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Khan R, Maheshwari V, Harris SH, Alam K: Prostatic adenocarcinoma metastasizing to the parietal bones. Indian J Pathol Microbiol; 2007 Oct;50(4):759-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma metastasizing to the parietal bones.
  • Prostate cancer metastasis to the axial skeleton occurs at high frequency in patients with advanced disease causing significant morbidity and mortality.
  • Parietal bone metastasis from prostatic adenocarcinoma was the initial presentation seen in our patient.
  • [MeSH-major] Adenocarcinoma / secondary. Parietal Bone / pathology. Prostatic Neoplasms / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306543.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


34. Tanaka R, Ishiyama T, Uchihara T, Inadome Y, Iijima T, Morishita Y, Kano J, Goya T, Noguchi M: Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer; 2006 Feb 1;106(3):648-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma.
  • METHODS: Surgically resected lung specimens were obtained from 32 patients with peripheral adenocarcinomas, and BI-1 gene expression was examined and compared with expression of the p53, bcl-2 and Bax genes.
  • BI-1 gene expression in tumor specimens was significantly higher in adenocarcinomas with bronchioloalveolar carcinoma (BAC) and in adenocarcinomas of mixed subtypes with bronchioloalveolar spreading (14 of 17 tumors; 82.4%) than in carcinomas without it spreading.
  • Patients who had BI-1-positive adenocarcinoma showed a relatively favorable prognosis compared with patients who had BI-1-negative adenocarcinoma.
  • CONCLUSIONS: BI-1 gene expression was restricted to tumor cells with lepidic growth and was a prognostic factor for peripheral-type adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Apoptosis / genetics. Lung Neoplasms / genetics. Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 16353209.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Proteins; 0 / Proteins; 0 / TMBIM6 protein, human
  •  go-up   go-down


35. Hu S, Hu CP, Liang CH: [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile]. Zhonghua Yi Xue Za Zhi; 2005 Jun 8;85(21):1493-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
  • OBJECTIVE: To study whether technetium-99m methoxyisobutyl isonitrile ((99m)Tc-MIBI) can be used to examine the drug resistance of lung adenocarcinoma cells and to explore the efficiency of gensenoside Rh2 in reversing the resistance of adenocarcinoma cells to cisplatin (DDP).
  • METHODS: Human lung adenocarcinoma cells of the line A549 sensitive to DDP and drug-resistant lung adenocarcinoma cells of the line A549DDP were cultured.
  • CONCLUSION: (99m)Tc-MIBI can be used to examine the resistance of lung adenocarcinoma A549DDP cells.
  • Gensenoside Rh2 of in-toxic concentration can reverse the resistance of lung adenocarcinoma A549DDP cells to cisplatin.
  • [MeSH-major] Adenocarcinoma / pathology. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Ginsenosides / pharmacology. Lung Neoplasms / pathology. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Drugs, Chinese Herbal / pharmacology. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Panax / chemistry. Random Allocation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061030.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Ginsenosides; 78214-33-2 / ginsenoside Rh2; 971Z4W1S09 / Technetium Tc 99m Sestamibi; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Leal M, Lima E, Silva P, Assumpção P, Calcagno D, Payão S, Burbano RR, Smith M: Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol; 2007 May 14;13(18):2568-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.
  • METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse-type gastric adenocarcinoma samples from individuals in Northern Brazil.
  • MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Proteins / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Acid Anhydride Hydrolases / genetics. Adult. Aged. Brazil. Cadherins / genetics. Cell Cycle Proteins / genetics. Female. Humans. Male. Microtubule-Associated Proteins / genetics. Middle Aged. Neoplasm Proteins / genetics. Promoter Regions, Genetic / physiology. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49868-73 [14506228.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):689-99 [14742272.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 5;1690(3):276-84 [15511635.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1448-51 [1997184.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):11-26 [8199193.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1595-604 [10587350.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2294-301 [11413518.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):399-403 [12163364.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):232-6 [12432269.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):988-1003 [12529403.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Yi Chuan Xue Bao. 2003 Feb;30(2):103-8 [12776596.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5653-8 [8971171.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2814-25 [9184226.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3429-34 [9699676.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23026-32 [9722527.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Dec;95(12):962-8 [15596045.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5174-9 [16127748.001]
  • [Cites] Rev Med Chil. 2005 Aug;133(8):874-80 [16163424.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):748-60 [16207477.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):64-72 [16081515.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):64-71 [16367923.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):199-203 [16482618.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1250-9 [16475210.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):24-9 [16531765.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):471-6 [16618867.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3216-21 [16707623.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):16-25 [17063461.001]
  • (PMID = 17552003.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / PLAGL1 protein, human; 0 / Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4146816
  •  go-up   go-down


37. Sepesi B, Watson TJ, Zhou D, Polomsky M, Litle VR, Jones CE, Raymond DP, Hu R, Qiu X, Peters JH: Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg; 2010 Apr;210(4):418-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.
  • BACKGROUND: Endoscopic resection and ablation have advanced the treatment of intramucosal esophageal adenocarcinoma and have been promoted as definitive therapy for selected superficial submucosal tumors.
  • STUDY DESIGN: An expert gastrointestinal pathologist retrospectively reviewed 54 T1 adenocarcinomas from 258 esophagectomy specimens (2000 to 2008).
  • Fisher's exact test and univariate and multivariate logistic regression were used to identify variables predicting nodal disease.
  • Univariate logistic regression identified poor differentiation (p = 0.024), lymphovascular invasion (p = 0.049), and number of harvested lymph nodes (p = 0.037) as significantly correlated with nodal disease.
  • CONCLUSIONS: All depths of submucosal invasion of esophageal adenocarcinoma were associated with an unacceptably high prevalence of nodal metastases and a marked increase relative to intramucosal cancer.
  • Accurate predictors of nodal spread, independent of tumor depth, are currently lacking and will be necessary before recommending endoscopic resection with or without concomitant ablation as curative treatment for even superficial submucosal neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagoscopy
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Confidence Intervals. Female. Humans. Kaplan-Meier Estimate. Logistic Models. Lymphatic Metastasis. Male. Middle Aged. Mucous Membrane / pathology. Mucous Membrane / surgery. Neoplasm Invasiveness. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Prevalence. Retrospective Studies. Treatment Outcome. Vascular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20347733.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol; 2008 Feb;3(2):111-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
  • BACKGROUND: Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarcinomas and have potential prognostic value in patients with advanced disease.
  • Whether EGFR and KRAS mutations also have an impact on survival in patients who undergo lung resection for curative intent in the absence of targeted therapy has not been established.
  • METHODS: We analyzed the clinical characteristics and outcomes data for 296 patients who underwent resection at our institution for stage I-III lung adenocarcinoma.
  • Patients with EGFR mutant tumors were more likely to be never smokers (48%), present with stage I disease (88%), and had a 90% (95% confidence interval [CI] 70-97%) 3-year overall survival, whereas patients with KRAS mutant tumors were more likely to be former/current smokers (92%), present with locally advanced disease (40%), and had a 66% (95% CI 48-79%) 3-year overall survival.
  • CONCLUSIONS: EGFR and KRAS mutations define distinct molecular subsets of resected lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Prognosis. Protein Kinase Inhibitors / pharmacology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303429.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


39. Deming D, Geiger P, Chen H, Kunnimalaiyaan M, Holen K: ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res; 2010 Jun 1;161(1):28-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines.
  • Here we determine the effects of ZM336372 on GSK-3beta phosphorylation, apoptosis, and growth in pancreatic adenocarcinoma cell lines.
  • An increase in cleaved PARP was demonstrated after treatment with both agents, as was seen previously with GSK-3beta inhibition in pancreatic adenocarcinoma cells.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. LITHIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Curr Drug Targets. 2006 Nov;7(11):1377-88 [17100578.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Nov;15(11):1395-410 [17040199.001]
  • [Cites] Surgery. 2007 Dec;142(6):959-64; discussion 959-64 [18063082.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):852-7 [18299943.001]
  • [Cites] Chem Biol. 2000 Oct;7(10):793-803 [11033082.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 26;280(3):720-5 [11162580.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):859-68 [11314019.001]
  • [Cites] Biochem J. 2001 Oct 1;359(Pt 1):1-16 [11563964.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jul;283(1):G204-11 [12065308.001]
  • [Cites] Trends Mol Med. 2002 Aug;8(8):385-9 [12127724.001]
  • [Cites] Neuropharmacology. 2002 Dec;43(7):1158-64 [12504922.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3243-51 [12761494.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):441-3 [12967765.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45937-45 [12928438.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3976-85 [8358726.001]
  • [Cites] Chem Biol. 1999 Aug;6(8):559-68 [10421767.001]
  • [Cites] Trends Pharmacol Sci. 2004 Sep;25(9):471-80 [15559249.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2076-81 [15781615.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):910-7 [15956248.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5074-81 [16951223.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1151-8 [17363508.001]
  • (PMID = 20031160.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109053; United States / NCI NIH HHS / CA / CA109053
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; G4962QA067 / Lithium Chloride
  • [Other-IDs] NLM/ NIHMS167512; NLM/ PMC3379885
  •  go-up   go-down


40. Saad RS, Lindner JL, Liu Y, Silverman JF: Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol; 2009 Jan;131(1):92-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma.
  • We studied tumor lymphatic vascular density (LVD) as a predictive marker for the risk of lymph node (LN) metastasis and its relationship to other prognostic parameters and survival in 75 patients with esophageal adenocarcinoma.
  • D2-40 LVD demonstrated a significant correlation with LN metastases, lymphovascular invasion, and tumor stage (r = 0.45, r = 0.47, and r = 0.37, respectively) and with shorter disease-free survival.
  • Our study showed that angiogenesis and lymphangiogenesis have important roles in the progression of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Lymphatic Vessels / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095571.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / monoclonal antibody D2-40
  •  go-up   go-down


41. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ: The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia; 2005 Jan;7(1):75-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.
  • The hepatocyte growth factor (HGF) receptor, Met, has established oncogenic properties; however, its expression and function in esophageal adenocarcinoma (EA) remain poorly understood.
  • Met expression was investigated in surgical specimens of EA, Barrett's esophagus (BE), and normal esophagus (NE) using immunohistochemistry (IHC) and quantitative reverse transcriptase polymerase chain reaction.
  • In contrast, minimal immunostaining was observed in BE without dysplasia or NE specimens.
  • Met dysregulation occurs early in Barrett's dysplasia to adenocarcinoma sequence.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5582-9 [11114738.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4041-8 [11751499.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):8-13 [11857377.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):411-21 [11864613.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):963-72 [11891194.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):406-7 [11904306.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):3813-20 [11911252.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5462-9 [14500382.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Aug 16;122(3):1450-9 [6477569.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3314-20 [2524251.001]
  • [Cites] J Cell Biol. 1990 Nov;111(5 Pt 1):2097-108 [2146276.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer Cells. 1991 Jun;3(6):227-32 [1832923.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Symp Soc Exp Biol. 1993;47:163-81 [8165564.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1963-70 [7728766.001]
  • [Cites] Cancer Lett. 1995 Nov 6;97(2):145-8 [7497455.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1115-25 [8622656.001]
  • [Cites] J Mol Med (Berl). 1996 Sep;74(9):505-13 [8892055.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):433-9 [9012470.001]
  • [Cites] J Pathol. 1996 Dec;180(4):389-94 [9014859.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5571-8 [9407969.001]
  • [Cites] Int J Oncol. 1998 Feb;12(2):325-8 [9458357.001]
  • [Cites] Laryngoscope. 1998 Sep;108(9):1413-7 [9738769.001]
  • [Cites] Oncogene. 1999 Sep 9;18(36):5120-5 [10490849.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2259-65 [10590366.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Digestion. 2000;61(4):237-46 [10878450.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 15720819.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA101958; United States / NCI NIH HHS / CA / R01 CA090665
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 67256-21-7 / Hepatocyte Growth Factor; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC1490312
  •  go-up   go-down


42. Johnson ML, Rizvi NA, Ginsberg MS, Miller VA, Kris MG, Pao W, Riely GJ: A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. J Clin Oncol; 2009 May 20;27(15_suppl):8012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations.
  • : 8012 Background: KRAS mutations are present in 30% of lung adenocarcinomas and are associated with primary resistance to erlotinib and gefitinib.
  • Salirasib was given orally, for days 1-28 of a 35 day cycle, with response assessment on day 28, day 63, and every 10 weeks (wks) thereafter.
  • CONCLUSIONS: After 10 wks of salirasib, 28% of previously treated pts with KRAS mutations and 38% of untreated pts had stable disease.
  • The successful enrollment over 15 months of 29 pts with tumors with known KRAS mutations demonstrates that trials of a KRAS-specific genotype in lung cancer are feasible, and should be standard in future studies targeting the KRAS pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962781.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hopwood P, Wallace WA, Cousens C, Dewar P, Muldoon M, Norval M, Griffiths DJ: Absence of markers of betaretrovirus infection in human pulmonary adenocarcinoma. Hum Pathol; 2010 Nov;41(11):1631-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of markers of betaretrovirus infection in human pulmonary adenocarcinoma.
  • A proportion of human pulmonary adenocarcinomas has been shown previously to express an antigen related to the Gag protein of a betaretrovirus, Jaagsiekte sheep retrovirus, that causes ovine pulmonary adenocarcinoma.
  • To investigate further the hypothesis that a retrovirus might be present in human lung adenocarcinoma, we examined specimens from patients with lung cancer for evidence of retroviral infection by immunohistochemistry, reverse transcriptase-polymerase chain reaction, immunoblotting and cDNA library screening.
  • Reverse transcriptase-polymerase chain reaction identified the expression of endogenous betaretroviruses in tumor tissue and in normal lung tissue, but no specific provirus was associated with tumor.
  • This study has confirmed the expression of a Jaagsiekte sheep retrovirus Gag-related antigen in some human lung tumors but additional evidence of betaretroviral infection was not obtained.
  • While these data do not rule out a role for a retrovirus in human pulmonary adenocarcinomas, they suggest that, if such a virus is present, it is unrelated to known betaretroviruses.
  • [MeSH-major] Adenocarcinoma / virology. Betaretrovirus / isolation & purification. Lung Neoplasms / virology. Retroviridae Infections / complications. Tumor Virus Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20825971.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/111
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gene Products, gag; 0 / RNA, Viral
  •  go-up   go-down


44. Pintor MF, Figueroa L, Martínez B: Polymorphous low grade adenocarcinoma: review and case report. Med Oral Patol Oral Cir Bucal; 2007 Dec;12(8):E549-51
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low grade adenocarcinoma: review and case report.
  • Polymorphous Low-Grade Adenocarcinoma is a rare, malignant salivary gland tumor, which is found almost exclusively in minor salivary glands.
  • This report describes the case of a patient that consulted at the Military Odontological Center (Central Odontológica del Ejército) due to an esthetic alteration of her dental prosthesis, which had been made 8 years before.
  • An incisional biopsy was carried out, and once the polymorphous low-grade adenocarcinoma diagnosis had been stated, the patient was sent to the Head and Neck Surgery Service of the Military Hospital, where the lesion was treated by wide surgical excision followed by radiation therapy.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059236.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


45. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N, Ohge H, Sueda T: Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg; 2008 Jun;195(6):757-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
  • METHODS: Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks.
  • According to the TNM system, 4 (15%), 2 (7%), 6 (22%), and 15 (56%) patients were diagnosed with stage IA, IB, IIA, and IIB disease, respectively.
  • Overall and disease-free survival rates were 86% and 60% at 1 year, 66% and 45% at 2 years, and 33% and 45% at 3 years, respectively.
  • CONCLUSIONS: Adjuvant gemcitabine plus S-1 chemotherapy appears to be a promising treatment for patients after surgical resection of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Pancreatectomy. Pancreaticoduodenectomy. Survival Rate. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367131.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


46. Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI: Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer; 2005 Nov 28;93(11):1301-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus 16 infection in adenocarcinoma of the cervix.
  • The impact of the success of organised cervical screening programme results in a steady decline of the incidence of squamous cell carcinoma of the cervix but a concomitant increase in the incidence of the less common histological subtypes, particularly adenocarcinoma of the cervix (ACC).
  • In this study, the cervical adenocarcinoma cells of a 10-year cohort of women diagnosed with ACC were dissected using the PixCell II Laser Microdissecting System to detect the HPV 16 genome sequence using the real-time quantitative polymerase chain reaction to confirm the presence of HPV DNA within ACC cells.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / genetics. Human papillomavirus 16 / pathogenicity. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33 [10423141.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Methods Mol Biol. 2005;293:27-37 [16028408.001]
  • [Cites] Lancet. 2000 Jun 24;355(9222):2194-8 [10881892.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):64-8 [10889904.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Oct;15(5):663-76 [11563866.001]
  • [Cites] Obstet Gynecol. 1980 Sep;56(3):361-4 [7422175.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):394-8 [1311392.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • (PMID = 16265348.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2361519
  •  go-up   go-down


47. Mitry E, Taleb-Fayad R, Deschamps A, Mansencal N, Lepère C, Declety G, Lièvre A, Vaillant JN, Lesur G, Cramer E, Dubourg O, Rougier P: Risk of venous thrombosis in patients with pancreatic adenocarcinoma. Gastroenterol Clin Biol; 2007 Dec;31(12):1139-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of venous thrombosis in patients with pancreatic adenocarcinoma.
  • AIM: To estimate the risk of venous thrombosis associated with pancreatic adenocarcinoma and its consequences on treatment and survival.
  • Pancreatic adenocarcinoma was histologically proved in 72 patients (81%) and was metastatic in 49 patients (54.4%).
  • The risk of venous thrombosis was significantly reduced by the use of anti-thrombotic prophylaxis (HR: 0.03 [95CI: 0.003-0.27]) and increased among patients with a biological inflammatory syndrome (HR: 9.0 [95CI: 2.30-34.4]) and metastatic disease (HR: 4.4 [95CI: 1.1-17.9]).
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Venous Thrombosis / etiology

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176374.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


48. Stephens MR, Hopper AN, Lewis WG, Blackshaw G, Edwards P, Osborne B, Thompson IW: Prognostic significance of gastrin expression in patients undergoing R0 gastrectomy for adenocarcinoma. Gastric Cancer; 2007;10(3):159-66
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of gastrin expression in patients undergoing R0 gastrectomy for adenocarcinoma.
  • METHODS: Eighty-six consecutive patients undergoing R0 gastrectomy for adenocarcinoma were studied.
  • CONCLUSION: The presence of GPT cells in patients with gastric adenocarcinoma is a significant and independent prognostic indicator.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastrectomy. Gastrins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Confidence Intervals. Female. Gene Expression. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922093.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


49. Kawate S, Takeyoshi I, Ikota H, Numaga Y, Sunose Y, Morishita Y: Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon. Jpn J Clin Oncol; 2005 Mar;35(3):154-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon.
  • This report presents a case of endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon following total abdominal hysterectomy and bilateral salpingo-oophorectomy for leiomyoma of the uterus and infiltrating pelvic endometriosis, and hormone replacement therapy.
  • Based on the diagnosis of mesocolonic tumor, sigmoidectomy with lymph node resection was performed.
  • The tumor cells were immunopositive for cytokeratin 7, but negative for cytokeratin 20, and the tumor was histologically diagnosed as endometrioid adenocarcinoma of the mesocolon.

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741306.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernández-Del Castillo C: Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg; 2008 Jun;32(6):1051-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma.
  • METHODS: We performed a retrospective review of 205 patients with ductal adenocarcinoma who underwent surgical resection between 1990 and 2003.
  • CONCLUSIONS: There is no evidence to support preoperative platelet count as either an adverse or favorable prognostic factor in pancreatic ductal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1493-8 [11677994.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1793-800 [16983701.001]
  • [Cites] J Clin Gastroenterol. 2002 Aug;35(2):180-4 [12172365.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1378-80 [12352397.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1098-106 [12783124.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2991-4 [12926151.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):211-4 [14751160.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1211-9 [15028825.001]
  • [Cites] Urology. 2004 Mar;63(3):447-50 [15028435.001]
  • [Cites] Respiration. 2004 Mar-Apr;71(2):170-3 [15031573.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):95-108 [15034801.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):137-42 [10926792.001]
  • [Cites] BJU Int. 2000 Aug;86(3):203-7 [10930915.001]
  • [Cites] Tumour Biol. 2000 Sep-Oct;21(5):309-14 [10940827.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3983-5 [11268488.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):236-40 [11437932.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):847-53 [15143932.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):364-7 [15157203.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2975-7 [1591690.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] J Intern Med. 1999 Mar;245(3):295-300 [10205592.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Surg. 2005 Mar;189(3):278-82 [15792750.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):859-63 [16469566.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2897-902 [16782929.001]
  • [Cites] Am J Surg. 2006 Sep;192(3):322-9 [16920426.001]
  • [Cites] Platelets. 2006 Aug;17(5):328-31 [16928605.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):287-91 [11923136.001]
  • (PMID = 18224462.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329; United States / NCI NIH HHS / CA / P01 CA117969
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS517395; NLM/ PMC3806089
  •  go-up   go-down


51. Ilson D, Bains M, Rizk N, Rusch V, Flores R, Park B, Shah M, Kelsen D, Miron B, Goodman K: Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis.
  • We are now combining in a Phase II trial Bev/I/C with concurrent radiotherapy (RT) in esophageal adenocarcinoma (EA) with the primary endpoint of safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963076.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Rossi A, Manto A, Maione P, Gridelli C: Synchronous bilateral retinal metastases from lung adenocarcinoma. Tumori; 2005 May-Jun;91(3):287-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous bilateral retinal metastases from lung adenocarcinoma.
  • Hematogenous retinal metastases from non-small cell lung cancer are rare, and are even more uncommonly observed bilaterally.
  • Non-small cell lung cancer usually metastasizes to the liver, adrenal glands, lung, bone, central nervous system, and kidney.
  • We report the case of a 41-year-old male patient with advanced lung adenocarcinoma heavily pretreated with polychemotherapy and palliative radiotherapy up to June 2003, when synchronous bilateral retinal metastases were diagnosed.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology. Retinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206660.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Turunen M, Talvensaari-Mattila A, Soini Y, Santala M: Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res; 2009 Dec;29(12):5185-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma.
  • CONCLUSION: Increased claudin-5 expression is associated with aggressive behavior in serous ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Claudin-5. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044634.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN5 protein, human; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


54. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.
  • BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Liu T, Tang H, Lang Y, Liu M, Li X: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett; 2009 Jan 18;273(2):233-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin.
  • Here, we show that miR-27a is up-regulated in human gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. MicroRNAs / physiology. Repressor Proteins / chemistry. Stomach Neoplasms / metabolism
  • [MeSH-minor] 3' Untranslated Regions. Binding Sites. Cell Line, Tumor. Cell Transformation, Neoplastic. Disease Progression. Green Fluorescent Proteins / metabolism. Humans. Oncogenes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789835.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / MIRN27 microRNA, human; 0 / MicroRNAs; 0 / Repressor Proteins; 0 / prohibitin; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


56. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR: MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics; 2010 May 06;3:16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.
  • BACKGROUND: MUC1 protein is highly expressed in lung cancer.
  • We characterized MUC1-CD-induced transcriptional changes and examined their significance in lung cancer patients.
  • We then examined expression of these genes in 441 lung adenocarcinomas from a publicly available database.
  • The MAPS was further validated for prognostic significance in 84 lung adenocarcinoma patients from an independent database.
  • CONCLUSIONS: The MAPS signature, comprised of MUC1-CD-dependent genes involved in the control of cell cycle and proliferation, is associated with poor outcomes in patients with adenocarcinoma of the lung.
  • These data provide potential new prognostic biomarkers and treatment targets for lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):353-7 [18552837.001]
  • [Cites] Biochem J. 2009 Mar 15;418(3):475-89 [19228121.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2833-7 [19318547.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5837-41 [19289846.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5133-41 [19491255.001]
  • [Cites] J Biol Chem. 2009 Jul 3;284(27):18085-95 [19416980.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35458-64 [12826677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Biotechniques. 2002 Feb;32(2):316, 318, 320 [11848408.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Genomics. 2003 Feb;81(2):202-9 [12620398.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6107-10 [12955090.001]
  • [Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):702-6 [14688481.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):163-75 [14998492.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20607-12 [14999001.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] BMC Genomics. 2004 Jul 19;5(1):47 [15260889.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3237-48 [15297875.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):553-63 [15380592.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):615-23 [8006075.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4B):2209-13 [8694545.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):667-71 [9930070.001]
  • [Cites] Ann Thorac Surg. 1999 Mar;67(3):810-4 [10215233.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1036-40 [15616564.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):167-78 [15710329.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10413-22 [16288032.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):473-83 [16500915.001]
  • [Cites] Virology. 2006 Sep 15;353(1):200-9 [16814354.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4539-44 [17008692.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):3-16 [17612486.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):601-13 [17710163.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):515-9 [17913444.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6380-5 [18427120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5 [19001271.001]
  • (PMID = 20459602.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097098; United States / NCI NIH HHS / CA / (R01) CA111423; United States / NCI NIH HHS / CA / (R01) CA97098
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1
  • [Other-IDs] NLM/ PMC2876055
  •  go-up   go-down


57. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA: Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol; 2005 Oct 10;23(29):7307-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
  • PURPOSE: Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity.
  • The purpose of this study was to investigate the involvement of the FGFR4 polymorphism in lung tumorigenesis.
  • PATIENTS AND METHODS: A case-control study was performed including 274 patients with histologically confirmed lung adenocarcinoma and 401 healthy control subjects from general population. mRNA expression analysis was carried out in healthy lung of cancer patients.
  • RESULTS: Patients with the Arg/Arg or Gly/Arg genotype compared to those with a Gly/Gly genotype had an earlier age at cancer onset (median age, 60.2 v 63.4 years), higher proportion of poor clinical stage disease (hazard ratio [HR], 2.3; 95% CI, 1.4 to 3.9; P = .002), of nodal involvement (HR, 1.9; 95% CI, 1.1 to 3.2; P = .027), or of short-term survivors (HR, 1.6; 95% CI, 1.1 to 2.3; P = .008).
  • CONCLUSION: This study suggests that FGFR4 Gly388Arg polymorphism may predict prognosis in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Receptor, Fibroblast Growth Factor, Type 4 / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061909.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4
  •  go-up   go-down


58. Balachandra B, Swanson PE, Upton MP, Yeh MM: Adenocarcinoma arising in a gastrocystoplasty. J Clin Pathol; 2007 Jan;60(1):85-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising in a gastrocystoplasty.
  • There are reports of adenocarcinomas arising in the setting of ileocystoplasty and colocystoplasty.
  • However, the first case of adenocarcinoma arising in the setting of a gastrocystoplasty is reported.
  • [MeSH-major] Adenocarcinoma / etiology. Stomach / transplantation. Urinary Bladder Neoplasms / etiology. Urinary Bladder, Neurogenic / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Aug;168(2):698-701; discussion 701 [12131353.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 2):1122-5 [10458445.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] J Urol. 1990 Nov;144(5):1283-7 [2231914.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] J Urol. 1993 Apr;149(4):731-4 [8455232.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):730-3 [8326635.001]
  • [Cites] Hum Pathol. 1994 Mar;25(3):221-6 [7512070.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):473-4 [8015094.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 2):720-4 [8022004.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] J Pediatr Surg. 1997 Dec;32(12):1757-8 [9434020.001]
  • [Cites] J Pediatr Surg. 1999 Apr;34(4):532-5 [10235315.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):143-7 [12754637.001]
  • (PMID = 17213351.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860596
  •  go-up   go-down


59. Ault GT, Nunoo-Mensah JW, Johnson L, Vukasin P, Kaiser A, Beart RW Jr: Adenocarcinoma arising in the middle of ileoanal pouches: report of five cases. Dis Colon Rectum; 2009 Mar;52(3):538-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising in the middle of ileoanal pouches: report of five cases.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis with or without mucosectomy has become the procedure of choice in patients with long-standing ulcerative colitis complicated by malignancy or medically refractory disease and for familial polyposis syndrome.
  • We present a recent series of five patients who developed adenocarcinoma in the middle of their ileal pouch including the first case of pouch carcinoma in a patient who underwent pouch formation for ulcerative colitis.
  • [MeSH-major] Adenocarcinoma / etiology. Anus Neoplasms / etiology. Colonic Pouches / adverse effects. Ileal Neoplasms / etiology
  • [MeSH-minor] Adenomatous Polyposis Coli / surgery. Adult. Anastomosis, Surgical / adverse effects. Colitis, Ulcerative / surgery. Colorectal Neoplasms / surgery. Female. Humans. Male. Middle Aged. Proctocolectomy, Restorative

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333060.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Baumgartner WA, Guzman DS, Hollibush S, Gaschen L, Hodgin EC, Mitchell MA: Bronchogenic adenocarcinoma in a hyacinth macaw (Anodorhynchus hyacinthinus). J Avian Med Surg; 2008 Sep;22(3):218-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchogenic adenocarcinoma in a hyacinth macaw (Anodorhynchus hyacinthinus).
  • On histologic examination, the diagnosis was primary pulmonary bronchial adenocarcinoma with spinal invasion.
  • [MeSH-major] Adenocarcinoma / veterinary. Bird Diseases / pathology. Lung Neoplasms / veterinary. Psittaciformes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19014095.001).
  • [ISSN] 1082-6742
  • [Journal-full-title] Journal of avian medicine and surgery
  • [ISO-abbreviation] J. Avian Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


62. Kubosawa H, Iwasaki H, Kuzuta N, Suzuki H, Iura H: Adenocarcinoma with peritoneal dissemination secondary to multiple mature teratomas of the omentum. Gynecol Oncol; 2006 Jun;101(3):534-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma with peritoneal dissemination secondary to multiple mature teratomas of the omentum.
  • There was a histologic evidence of a sequential transition from benign through borderline to obviously invasive adenocarcinoma within the lining of the cysts as well as peritoneal dissemination.
  • CONCLUSION: We defined the present case as malignant transformation of a mature teratoma, but have no evidence whatsoever for the origin of multiple mature teratomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Neoplasms, Multiple Primary / pathology. Omentum / pathology. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488467.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z, Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol; 2010 Dec 15;330(1-2):10-6
Hazardous Substances Data Bank. ANDROSTENEDIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells.
  • The purpose of this study was to investigate the effects of testosterone and androstenedione on the viability of an ovarian adenocarcinoma cell line, the activity and expression of telomerase, and the phosphorylation status of its catalytic subunit in these cells.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Ovarian Neoplasms / enzymology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20673788.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


64. Mamat S, Ikeda J, Enomoto T, Ueda Y, Rahadiani N, Tian T, Wang Y, Qiu Y, Kimura T, Aozasa K, Morii E: Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep; 2010 May;23(5):1221-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
  • High level of CDCP1 expression proved to be a poor prognosticator for lung adenocarcinoma.
  • Here, expression level of CDCP1 was immunohistochemically examined in 110 cases (median age of 54.7 years) of endometrioid adenocarcinoma, and its clinical implications were evaluated.
  • These suggested that the attitude of CDCP1 in cancers of lung and endometrium was different.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Adhesion Molecules / analysis. Endometrial Neoplasms / chemistry. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372833.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


65. Chicos SC, Beznea A, Chebac GR, Ceauşu M, Ceauşu M: [The Krukenberg tumor caused by an adenocarcinoma of the gallbladder]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):481-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Krukenberg tumor caused by an adenocarcinoma of the gallbladder].
  • [Transliterated title] Tumoră Krukenberg secundară unui adenocarcinom al veziculei biliare.
  • This work presents the case of a 62 year-old woman's Krukenberg tumor caused by an adenocarcinoma of the gallbladder.
  • This was the presumptive diagnosis that was confirmed during the operation.
  • The paraclinical investigations (echography, computerised tomography) were not able to specify the diagnosis before the operation.
  • [MeSH-major] Adenocarcinoma / secondary. Gallbladder Neoplasms / pathology. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Ascites / etiology. Cholecystectomy. Fatal Outcome. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966948.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


66. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell; 2005 May;7(5):469-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
  • To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.
  • These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.

  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - 129S/Sv-Kras<tm4Tyj>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Cell. 2005 May;7(5):405-7 [15894260.001]
  • (PMID = 15894267.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK60694; United States / NCI NIH HHS / CA / R25-CA87812; United States / NIA NIH HHS / AG / K08 AG001019; United States / NCI NIH HHS / CA / R01 CA101973; United States / NCI NIH HHS / CA / P50-CA-62924; United States / NCI NIH HHS / CA / U01CA084291
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Oncogene Proteins v-erbB; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / pancreatic and duodenal homeobox 1 protein; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


67. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM: Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res; 2007 May 15;13(10):2946-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression signature predicts recurrence in lung adenocarcinoma.
  • PURPOSE: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection.
  • EXPERIMENTAL DESIGN: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection.
  • RESULTS: Cox proportional hazards modeling with leave-one-out cross-validation identified a 54-gene signature capable of predicting risk of recurrence in two independent validation cohorts of 55 adenocarcinomas [log-rank P=0.039; hazard ratio (HR), 2.2; 95% confidence interval (95% CI), 1.1-4.7] and 40 adenocarcinomas (log-rank P=0.044; HR, 3.3; 95% CI, 1.4-7.9).
  • In a subset of earliest stage adenocarcinomas, generally expected to have good outcome, the signature predicted samples with significantly poorer survival.
  • CONCLUSIONS: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. Gene Expression Profiling. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Female. Genes, Neoplasm. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Risk

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


68. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholomé K, Timmer J, Walch AK, Höfler H, Werner M: Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest; 2009 Apr;89(4):385-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays.
  • We performed genome-wide analysis of copy-number changes and loss of heterozygosity (LOH) in Barrett's esophageal adenocarcinoma by single nucleotide polymorphism (SNP) microarrays to identify associated genomic alterations.
  • DNA from 27 esophageal adenocarcinomas and 14 matching normal tissues was subjected to SNP microarrays.
  • Previously described genomic alterations in esophageal adenocarcinomas could be confirmed by SNP microarrays, such as amplification on 8q (CMYC, confirmed by FISH) and 20q13 or deletion/LOH on 3p (FHIT) and 9p (CDKN2A).
  • Using this technique, we identified several novel genes and DNA regions associated with esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663352.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Solomon N, Zhuge Y, Cheung M, Franceschi D, Koniaris LG: The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol; 2010 Mar;17(3):791-803
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma.
  • OBJECTIVE: Using a population-based registry, we evaluated the impact of neoadjuvant radiotherapy and lymphadenectomy on survival of patients undergoing curative-intent surgery for esophageal adenocarcinoma (EAC).
  • METHODS: Surveillance, Epidemiology, and End Results (SEER) data for patients with esophageal adenocarcinoma from 1988 to 2005 were queried.
  • Multivariate analysis showed age <65 years, well-differentiated tumor, local disease, negative lymph node status, adequate lymphadenectomy, and neoadjuvant radiotherapy to be independent predictors of improved survival.
  • Patients who have clinically node-positive disease should undergo both neoadjuvant radiation and adequate lymphadenectomy to ensure optimal outcome.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Esophageal Neoplasms / radiotherapy. Lymph Node Excision. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Mar;17(3):676-8 [19953331.001]
  • (PMID = 19953332.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Corporaal S, Smit WM, Russel MG, van der Palen J, Boot H, Legdeur MC: Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. Neth J Med; 2006 May;64(5):141-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
  • BACKGROUND: Inoperable or metastatic oesophagogastric adenocarcinoma has a poor prognosis.
  • METHODS: Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003.
  • RESULTS: The overall response rate was 57%; another 26% achieved stable disease and only 17% had progressive disease.
  • CONCLUSION: Capecitabine in combination with epirubicin and cisplatin is an effective and safe alternative to ECF, without the risks of a continuous venous access.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702612.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Kwon YW, Chang IH, Kim KD, Kim YS, Myung SC, Kim MK, Kim TH: Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma. Korean J Urol; 2010 Jul;51(7):456-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma.
  • We also sought to determine the prognostic value of these markers for patients with prostate adenocarcinoma.
  • The immunoreactivity of these proteins was stratified on a scale of 0 to 3 and was correlated with the pathologic features of prostate adenocarcinoma.
  • This finding could aid in identifying aggressive CaP.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27 [16492908.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] FEBS Lett. 1999 Feb 26;445(2-3):265-8 [10094469.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):190-9 [9920410.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2415-21 [9703888.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] Trends Biochem Sci. 1996 Apr;21(4):134-40 [8701470.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Gene. 1993 Dec 15;135(1-2):229-38 [8276262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2504-8 [1372446.001]
  • [Cites] Biochem Biophys Res Commun. 1965 Jun 9;19(6):739-44 [4953930.001]
  • [Cites] Curr Opin Urol. 2004 May;14(3):143-9 [15069304.001]
  • [Cites] Methods Mol Biol. 2002;172:69-80 [11833360.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):409-16 [11875708.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7999-8004 [11691825.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):707-12 [11510959.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):599-612 [11304580.001]
  • [Cites] Histol Histopathol. 2000 Oct;15(4):1271-84 [11005251.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1473-9 [11076656.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):345-9 [10956408.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • (PMID = 20664777.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2907493
  • [Keywords] NOTNLM ; Prostatic hyperplasia / Prostatic neoplasms / S100A2 protein, human / S100A4 protein, human
  •  go-up   go-down


72. Ikeda M, Kurose A, Takatori E, Sugiyama T, Traganos F, Darzynkiewicz Z, Sawai T: DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. Int J Oncol; 2010 May;36(5):1081-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.
  • Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma cell lines (HEC-1A, HEC-1B, Ishikawa, KLE) correlating the drug-induced increases in phosphorylated H2AX (gammaH2AX) with cell cycle phase, induction of apoptosis and induction of cell senescence, the latter detected by analysis of beta-galactosidase.
  • The data suggest that the treatment of endometrioid adenocarcinoma with these drugs may have to be customized to individual patients.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] DNA Repair (Amst). 2009 Sep 2;8(9):1038-46 [19482564.001]
  • [Cites] Oral Oncol. 1998 May;34(3):198-203 [9692054.001]
  • [Cites] J Oral Pathol Med. 1998 Sep;27(8):367-75 [9736425.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] Blood. 2000 Jul 1;96(1):307-13 [10891466.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):657-63 [11259608.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):262-72 [11795881.001]
  • [Cites] Radiat Res. 2002 Oct;158(4):486-92 [12236816.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):457-63 [12580960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4347-50 [12907603.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Oct;30(11):1855-8 [14619538.001]
  • [Cites] Cytometry A. 2004 Apr;58(2):99-110 [15057963.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Aug 30;123(1):291-8 [6477583.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] Vet Pathol. 1998 Nov;35(6):461-78 [9823588.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):539-45 [10203588.001]
  • [Cites] J Cell Biochem. 1999 May 1;73(2):259-77 [10227389.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):905-16 [10477747.001]
  • [Cites] Cytometry A. 2005 Nov;68(1):1-9 [16184611.001]
  • [Cites] Cancer Biol Ther. 2006 Aug;5(8):959-64 [16760673.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5775-82 [17124492.001]
  • [Cites] Cytometry A. 2007 Nov;71(11):905-14 [17879239.001]
  • [Cites] Yakugaku Zasshi. 2007 Nov;127(11):1837-42 [17978559.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):803-8 [18283299.001]
  • [Cites] Cytometry A. 2008 Jun;73(6):480-9 [18459160.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • (PMID = 20372780.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA028704-30; United States / NCI NIH HHS / CA / R01 CA028704; United States / NCI NIH HHS / CA / R01 CA028704-30
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS247428; NLM/ PMC2972583
  •  go-up   go-down


73. Kaur J, Dey P: Mean nuclear volume in complex atypical hyperplasia and adenocarcinoma of the endometrium. Anal Quant Cytol Histol; 2010 Oct;32(5):291-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mean nuclear volume in complex atypical hyperplasia and adenocarcinoma of the endometrium.
  • OBJECTIVE: To explore the possible role of mean nuclear volume (MNV) in differentiating complex atypical hyperplasia (CAH) from well-differentiated adenocarcinoma (WDAC) of the endometrium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22043505.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kozawa E, Matsuo Y, Hasegawa K, Fujiwara K, Sakurai T, Kimura F: Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings. Magn Reson Med Sci; 2010;9(4):233-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings.
  • Magnetic resonance (MR) imaging revealed an irregular ovarian wall with a solid component and a fluid-fluid level in the cystic mass and the pelvic space, which was thought to be pathognomonic for the rupture of an endometrioma with a malignant ovarian tumor.
  • Histologic examination following adnexectomy revealed a ruptured endometrioma associated with endometrioid adenocarcinoma.
  • A fluid-fluid level in the cystic mass and pelvic space may be pathognomonic MRI feature for a rupture of either an endometrioma or an endometrioma with a malignant tumor.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Diagnosis, Differential. Female. Humans. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187693.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Lazarev AF, Kobiakov DS, Klimachev VV, Avdalian AM, Bobrov IP: [Argyrophilic nucleolar organizer region associated proteins in adenomas with varying colonic dysplasia and adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):16-20
Hazardous Substances Data Bank. SILVER NITRATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Argyrophilic nucleolar organizer region associated proteins in adenomas with varying colonic dysplasia and adenocarcinoma].
  • There were statistically significant differences in the quantity, area, area index of Ag-NOR proteins between the groups: the mucosa (lower 2/3 crypts), mild, moderate, and severe dysplasia of adenoma.
  • Only the estimation of the area index of Ag-NOR proteins indicated statistically significant differences between severe dysplasia and highly differentiated adenocarcinoma.
  • Colonic adenomas showed a correlation of the activity of Ag-NOR proteins with epithelial dysplasia, but no correlation with the size and histological type of their structure.
  • [MeSH-major] Adenocarcinoma. Adenoma. Antigens, Nuclear / metabolism. Colonic Neoplasms. Intestinal Mucosa

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086631.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins; 95IT3W8JZE / Silver Nitrate
  •  go-up   go-down


76. Ebert S, Pilgram SM, Bähr M, Kermer P: Bilateral ophthalmoplegia due to symmetric cavernous sinus metastasis from gastric adenocarcinoma. J Neurol Sci; 2009 Apr 15;279(1-2):106-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ophthalmoplegia due to symmetric cavernous sinus metastasis from gastric adenocarcinoma.
  • We report a patient with rapidly progressive bilateral total ophthalmoplegia due to bilateral cavernous sinus metastasis from gastric adenocarcinoma.
  • Our patient impressively demonstrates the relevance of this differential diagnosis of bilateral ophthalmoplegia.
  • Repeated CCTs and cMRIs were required to find the diagnosis and finally start a therapy, demonstrating that even with advanced neuroradiological techniques, repetition of imaging within short intervals can be necessary to detect rapidly developing metastatic infiltrations as early as possible.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / complications. Brain Neoplasms / secondary. Cavernous Sinus. Ophthalmoplegia / etiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187943.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Seux M, Iovanna J, Dagorn JC, Dusetti NJ: MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology; 2009;9(1-2):66-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues.
  • In this review, we summarize recent knowledge about miRNA expression in pancreatic ductal adenocarcinoma, their possible molecular implications, and finally, we discuss the possible repercussion of these findings in terms of diagnosis and treatment of this disease.
  • [MeSH-major] Adenocarcinoma / genetics. MicroRNAs / metabolism. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077456.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Number-of-references] 58
  •  go-up   go-down


78. McMahon CJ, Smith MP: Magnetic resonance imaging in locoregional staging of rectal adenocarcinoma. Semin Ultrasound CT MR; 2008 Dec;29(6):433-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in locoregional staging of rectal adenocarcinoma.
  • A comprehensive overview of the current status of magnetic resonance imaging (MRI) in the locoregional assessment and management of rectal adenocarcinoma is presented.
  • [MeSH-major] Adenocarcinoma / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology
  • [MeSH-minor] Humans. Image Interpretation, Computer-Assisted. Neoplasm Staging. Prognosis. Rectum / anatomy & histology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166041.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 141
  •  go-up   go-down


79. Tanaka Y, Suzuki N, Takao M, Ichikawa A, Susumu N, Aoki D: Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. Gynecol Oncol; 2005 Nov;99(2):500-3
Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma.
  • BACKGROUND: Paraneoplastic cerebellar degeneration (PCD) is rarely caused by fallopian tube adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Fallopian Tube Neoplasms / complications. Paraneoplastic Cerebellar Degeneration / etiology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126258.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A24 Antigen
  •  go-up   go-down


80. Basile JR, Lin YL: A salivary gland adenocarcinoma mimicking a microcystic adnexal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):e28-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A salivary gland adenocarcinoma mimicking a microcystic adnexal carcinoma.
  • The microcystic adnexal carcinoma (MAC) is a rare, slow-growing but locally aggressive neoplasm arising in the midface and lips of middle-aged adults.
  • We describe a salivary gland adenocarcinoma arising in the lower lip, characterized by ductal structures and cords, 3-5 cell layers in thickness, set in a dense fibrous stroma and also invading nerves, thus mimicking a MAC in both its clinical and its histopathologic appearance.
  • The diagnostic dilemma presented by this lesion is discussed, along with a differential diagnosis and brief review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Skin Appendage / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Biopsy. Cell Nucleus / ultrastructure. Cell Proliferation. Connective Tissue / pathology. Cytoplasm / ultrastructure. Diagnosis, Differential. Female. Fibrosis. Humans. Lip / innervation. Middle Aged. Neoplasm Invasiveness. Sclerosis

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [CommentIn] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Sep;112(3):284-6 [21684772.001]
  • (PMID = 20303043.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


81. Bi R, Sheng W, Wang J: Collision tumor of the stomach: gastric adenocarcinoma intermixed with gastrointestinal stromal tumor. Pathol Int; 2009 Dec;59(12):880-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the stomach: gastric adenocarcinoma intermixed with gastrointestinal stromal tumor.
  • The tumor was composed of gastric adenocarcinoma and gastrointestinal stromal tumor, in which the two components were intermixed with each other.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrointestinal Stromal Tumors / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021614.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


82. Zhang X, Watson DI, Jamieson GG: Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction. Chin Med J (Engl); 2007 Dec 20;120(24):2268-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.
  • BACKGROUND: Esophageal adenocarcinoma is becoming an increasingly important problem.
  • The aim of this study was to evaluate the relationship between tumor invasion depth and lymph node metastasis for adenocarcinoma of the esophagus and esophagogastric junction, and to analyze the impact of lymph node metastases on survival of the patients.
  • METHODS: The study group comprised 121 patients with adenocarcinoma of the esophagus or esophagogastric junction, who underwent esophagectomy between January 1985 and December 2003 at either the Royal Adelaide Hospital or the Flinders Medical Center, Australia.
  • CONCLUSIONS: There is a close association between tumor invasion depth and lymph node metastasis for adenocarcinoma of the esophagus and esophagogastric junction.
  • Both the lymph node status and the number of metastatic nodes are important prognostic factors for the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167216.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • In multivariate survival analysis with Cox proportional hazards model, leptin expression was an independent prognostic marker of disease-free survival (p = 0.009).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


84. Wen J, Duan Y, Zou Y, Nie Z, Feng H, Lugnani F, Baust JG: Cryoablation induces necrosis and apoptosis in lung adenocarcinoma in mice. Technol Cancer Res Treat; 2007 Dec;6(6):635-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryoablation induces necrosis and apoptosis in lung adenocarcinoma in mice.
  • This study evaluated cryoablation on subcutaneously transplanted tumors of lung adenocarcinoma LA795 in T739 mice in vivo, in an effort to assess the feasibility of cryoablation in treatment of NSCLC.
  • Subcutaneously transplanted lung adenocarcinoma LA795 was implanted into T739 mice yielding tumors of approximately 2.5 cm in diameter.
  • [MeSH-major] Adenocarcinoma / surgery. Apoptosis. Cryosurgery. Lung Neoplasms / surgery. Necrosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17994794.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / bcl-2-Associated X Protein; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly (ADP-Ribose) Polymerase-1; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


85. Xavier MH, Vergueiro Tde R, Vilar EG, Pinto JM, Issa MC, Pereira GB, Carocha AP: Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation. Dermatol Online J; 2008;14(11):8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
  • The skin is an uncommon site for distant metastasis; when it is present the most common sources are breast, lung, and colon.
  • Metastasis generally occurs after an internal malignancy had been discovered and signifies disseminated disease with a poor prognosis.
  • We report an exuberant and rare case of cutaneous metastasis from gastric adenocarcinoma as the first sign of this serious visceral cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cachexia / etiology. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Spinal Neoplasms / drug therapy. Spinal Neoplasms / secondary. Treatment Failure

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094846.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Stein HJ, Hutter J, Feith M, von Rahden BH: Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg; 2007;19(1):72-8
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus.
  • The need for radical resection and extensive lymphadenectomy for early adenocarcinoma of the distal esophagus has recently been challenged.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Jejunal Diseases / surgery. Jejunum / surgery
  • [MeSH-minor] Catheter Ablation. Disease Progression. Esophagectomy. Humans. Lymph Node Excision. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403461.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


87. Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH: [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Sep;35(9):523-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
  • OBJECTIVE: To study the gain of chromosome 8 and c-myc gene and lipoprotein lipase gene status in prostatic adenocarcinoma of Chinese patients, and to analyze the relationship between chromosome 8 alterations and Gleason score of prostatic cancer.
  • METHODS: Formalin-fixed, paraffin-embedded prostatic biopsy tissues from 34 Chinese patients with untreated prostatic adenocarcinoma were studied by three-color fluorescence in situ hybridization (FISH) using ProVysion(TM) probe kit.
  • CONCLUSIONS: Alterations in chromosome 8 are common in prostatic adenocarcinoma occurring in Chinese patients.
  • Our data suggest that chromosome 8 alterations may play some roles in the development and progression of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134545.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


88. Uyama R, Hong SH, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M, Tsujimoto H, Nishimura R, Sasaki N: Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci; 2005 Dec;67(12):1273-6
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of eight feline mammary adenocarcinoma cell lines.
  • Eight new feline mammary adenocarcinoma cell lines derived from either primary or metastatic lesions were established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397390.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


89. Saha AK, Sutton CD, Sue-Ling H, Dexter SP, Sarela AI: Comparison of oncological outcomes after laparoscopic transhiatal and open esophagectomy for T1 esophageal adenocarcinoma. Surg Endosc; 2009 Jan;23(1):119-24
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of oncological outcomes after laparoscopic transhiatal and open esophagectomy for T1 esophageal adenocarcinoma.
  • INTRODUCTION: This study compared pathological characteristics and patterns of disease recurrence for patients with pT1 esophageal adenocarcinoma treated with either laparoscopic transhiatal esophagectomy or open esophagectomy.
  • METHODS: From January 2000-December 2006, 44 patients had pT1 esophageal adenocarcinoma after esophagectomy.
  • All patients in the laparoscopic group had N0 disease; none received adjuvant treatment.
  • Two patients (7%) in the open group had N1 disease, of whom one patient received adjuvant chemotherapy.
  • This patient had poorly differentiated N0 disease which was limited to the mucosa and died at 24 months.
  • Two patients in the open group developed recurrence, at 6 months (N0 disease with submucosal invasion) and 8 months (N1 disease with submucosal invasion) and died at 7 and 14 months, respectively.
  • The second patient with N1 disease is alive and well at 14 months.
  • CONCLUSIONS: As compared with open transthoracic esophagectomy, there is no oncological detriment in the treatment of pT1 esophageal adenocarcinoma by laparoscopic transhiatal esophagectomy.
  • The incidence of recurrence is small (7%) but can occur even in patients with tumour limited to the mucosa or N0 disease.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626700.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Rocha FT, Lourenço LG, Jucá MJ, Costa V, Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras; 2009 May-Jun;24(3):189-94
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
  • PURPOSE: To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent gastrojejunostomy.
  • RESULTS: Comparison between groups 2 and 3 relative to the presence of adenocarcinoma showed a statistically significant difference (p=0.0023).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504000.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


91. Airoldi M, Cattel L, Passera R, Pedani F, Milla P, Zanon C: Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas; 2006 Jan;32(1):44-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
  • OBJECTIVES: This phase 2 study evaluated clinical efficacy, toxicity, and pharmacokinetics of combination gemcitabine (GEM) and oxaliplatin (OXA) in patients with advanced pancreatic adenocarcinoma.
  • METHODS: Of 30 eligible patients, 20 had metastatic disease and 10 had nonmetastatic unresectable locally advanced disease.
  • RESULTS: Of 30 patients evaluated, 9 had a partial response, 11 had disease stabilization, and 10 had disease progression.
  • CONCLUSIONS: The combination of GEM and OXA was well tolerated and showed a promising activity in patients with advanced pancreatic adenocarcinoma; no sequence-dependent pharmacokinetic interaction occurred when comparing the GEM-OXA versus the OXA-GEM sequence, with a 24-hour interval.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Deoxycytidine / analogs & derivatives. Organoplatinum Compounds / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340743.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


92. Wang GQ, Jiao GG, Song JX, Fang WH, Lü N, Lin DM, Xie YQ, Zhang JH, Wei WQ: [Diagnosis and long-term results of surgical resection of early cardiac adenocarcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Jul 15;46(14):1045-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and long-term results of surgical resection of early cardiac adenocarcinoma].
  • OBJECTIVE: To summarize therapeutic experience and the long-term results of early cardiac adenocarcinoma with surgical resection.
  • METHODS: Ninety cases were diagnosed with early cardiac adenocarcinoma during endoscopic screening in high incidence rate area of esophageal cancer from 1972 to 1997.
  • CONCLUSIONS: Early diagnosis and early treatment may be the best approach for promoting the survival of the cardiac cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094526.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


93. Di Lauro L, Nunziata C, Arena MG, Foggi P, Sperduti I, Lopez M: Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2007 Sep 3;97(5):593-7
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
  • This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • The irinotecan, docetaxel and oxaliplatin combination chemotherapy is an active and well-tolerated novel regimen for treating metastatic gastric or GEJ adenocarcinoma and deserves further evaluation in randomised trials and in combination with molecular targeting agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Diarrhea / chemically induced. Disease Progression. Female. Fever / chemically induced. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mucositis / chemically induced. Neoplasm Metastasis. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):371-9 [10448285.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1402-6 [16641896.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):221-31 [16770784.001]
  • [Cites] Future Oncol. 2006 Oct;2(5):603-20 [17026452.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):315-24 [17376598.001]
  • [Cites] Stat Med. 2001 Mar 30;20(6):859-66 [11252008.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1204-9 [15277259.001]
  • (PMID = 17667920.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2360369
  •  go-up   go-down


94. Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac adenocarcinoma in five dogs. Vet Surg; 2006 Apr;35(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of metastatic anal sac adenocarcinoma in five dogs.
  • OBJECTIVE: To identify survival and morbidity information after surgery for metastases from apocrine gland anal sac adenocarcinomas (AGACA).
  • CONCLUSION: Dogs with anal sac adenocarcinoma metastases to the iliac lymph nodes can experience long-term survival after surgical excision of the metastatic lesion.
  • CLINICAL RELEVANCE: Lymphadenectomy may afford long-term survival to patients with metastatic anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Anal Sacs. Dog Diseases / surgery
  • [MeSH-minor] Animals. Dogs. Female. Lymph Node Excision / veterinary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Texas / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compend Contin Educ Vet. 2008 Feb;30(2):69, 72 [23713167.001]
  • (PMID = 16635006.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer; 2006 Sep 15;119(6):1491-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent EGFR mutations in brain metastases of lung adenocarcinoma.
  • Lung adenocarcinomas often metastasize to the brain, and the prognosis of patients with brain metastases is still very poor.
  • The epidermal growth factor receptor (EGFR) gene is mutated in a considerable fraction of primary lung adenocarcinomas, in particular those with drastic response to EGFR tyrosine kinase inhibitors.
  • EGFR mutations were detected in 12 of 19 metastatic lung adenocarcinomas to the brain (63%).
  • This frequency was higher than those in previous studies for EGFR mutations at various stages of lung adenocarcinoma in East Asia, including Japan (i.e., 20-55%).
  • In 6 cases with EGFR mutations, the corresponding primary lung tumors were also examined for the mutations, and in all of them, the same types of EGFR mutations were detected also in the primary tumors.
  • These findings will be highly informative for treatment of metastatic lung adenocarcinoma to the brain.
  • [MeSH-major] Adenocarcinoma / genetics. Brain Neoplasms / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Apr 15;120(8):1828-31; author reply 1832-3 [17236198.001]
  • (PMID = 16642476.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


96. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL: Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer; 2010 Nov 15;116(22):5200-6
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
  • BACKGROUND: Gemcitabine (2',2'-difluorodeoxycytidine) administration after resection of pancreatic cancer improves both disease-free survival (DFS) and overall survival (OS).
  • METHODS: Forty-five patients with resected pancreatic adenocarcinoma received adjuvant gemcitabine based-therapy in the context of multicenter phase 2 studies.
  • CONCLUSIONS: dCK protein expression was identified as an independent and strong prognostic factor in patients with resected pancreatic adenocarcinoma who received adjuvant gemcitabine therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / surgery. Deoxycytidine / analogs & derivatives. Deoxycytidine Kinase / metabolism. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / enzymology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20669326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.1.74 / Deoxycytidine Kinase
  •  go-up   go-down


97. Pedrazzani C, Bernini M, Giacopuzzi S, Pugliese R, Catalano F, Festini M, Rodella L, de Manzoni G: Evaluation of Siewert classification in gastro-esophageal junction adenocarcinoma: What is the role of endoscopic ultrasonography? J Surg Oncol; 2005 Sep 15;91(4):226-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Siewert classification in gastro-esophageal junction adenocarcinoma: What is the role of endoscopic ultrasonography?
  • BACKGROUND: Preoperative assessment of gastro-esophageal junction (GEJ) adenocarcinoma stage and its location according to Siewert are essential for planning the therapeutic approach.
  • The present study was aimed at analyzing the utility of endoscopic ultrasonography (EUS) in evaluating GEJ adenocarcinoma stage and whether this modality added to EGD improves assessment of Siewert type.
  • This goal was not achieved because of a high rate of advanced tumors less than 4 cm (sensitivity and specificity were 81.3% and 34.2%, respectively).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Endosonography. Esophageal Neoplasms / pathology. Esophageal Neoplasms / ultrasonography. Neoplasm Staging / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagogastric Junction. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16121346.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, Friess H: Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol; 2008 Aug;33(2):297-308
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
  • CXC chemokines have a major influence on the angiogenesis, growth and metastatic potential of pancreatic ductal adenocarcinoma.
  • CXCL16 and the receptor CXCR6 are upregulated in pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis tissues in contrast to normal pancreatic tissues at the mRNA and protein levels.
  • In conclusion, CXCL16 in both transmembrane and soluble forms, and its receptor CXCR6, seem to play an important role in the pathobiology of pancreatic cancer and might be potential markers for pancreatic cancer diagnosis and a target for multimodal therapy concepts in the future.
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Humans. Immunoblotting. Immunohistochemistry. Neoplasm Invasiveness / pathology. RNA, Messenger / analysis. Receptors, Chemokine / metabolism. Receptors, Virus / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636150.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL16 protein, human; 0 / CXCR6 protein, human; 0 / Chemokines, CXC; 0 / RNA, Messenger; 0 / Receptors, Chemokine; 0 / Receptors, Scavenger; 0 / Receptors, Virus
  •  go-up   go-down


99. Devalapally H, Duan Z, Seiden MV, Amiji MM: Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res; 2008 May 15;14(10):3193-203
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
  • PURPOSE: To modulate intracellular ceramide levels and lower the apoptotic threshold in multidrug-resistant ovarian adenocarcinoma, we have examined the efficacy and preliminary safety of tamoxifen coadministration with paclitaxel in biodegradable poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticles.
  • EXPERIMENTAL DESIGN: In vitro cytotoxicity and proapoptotic activity of paclitaxel and tamoxifen, either as single agent or in combination, was examined in wild-type (SKOV3) and MDR-1-positive (SKOV3TR) human ovarian adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ceramides / metabolism. Drug Delivery Systems / methods. Drug Resistance, Neoplasm / drug effects. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483388.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; 0 / Polyesters; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 24980-41-4 / polycaprolactone; 30IQX730WE / Polyethylene Glycols; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


100. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowskal H, Strzelczyk J, Janiak A, Malecka-Panas E: Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepatogastroenterology; 2006 Jul-Aug;53(70):608-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis.
  • BACKGROUND/AIMS: Pancreatic adenocarcinoma (PA) has a very poor prognosis.
  • The purpose of the study was to compare the prevalence of p53 mutations in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.
  • METHODOLOGY: We examined 49 patients who underwent Whipple resection or distal pancreatectomy for pancreatic adenocarcinoma (26 subjects) or chronic pancreatitis (23 subjects).
  • Our results indicate that p53 gene mutation may provide an additional tool in differential diagnosis of CP and PC.
  • [MeSH-major] Adenocarcinoma / genetics. Diagnosis, Differential. Genes, p53. Mutation. Pancreatic Neoplasms / genetics. Pancreatitis / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Chronic Disease. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Prevalence

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995472.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement